QURE · Uniqure N.V. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | $1.69M | $1.27M | $65.0K | $1.25M | $24.98M | $2.90M |
| Gross Profit | - | - | - | - | - | - |
| R&D | $140.67M | $143.78M | $214.86M | $197.59M | $143.55M | $122.40M |
| SG&A | $65.46M | $52.66M | $74.59M | $55.06M | $56.29M | $42.58M |
| Total Operating Expenses | $207.81M | $214.77M | $303.08M | $255.99M | $224.81M | $164.98M |
| D&A | $12.64M | $10.10M | $10.30M | $8.54M | $10.65M | $5.70M |
| Operating Income | ($185.35M) | ($184.29M) | ($282.87M) | ($143.16M) | $310.62M | ($125.43M) |
| Interest Expense | $61.99M | $63.74M | $41.56M | $11.70M | $7.47M | $3.83M |
| Income Tax | $5.63M | $2.43M | $1.92M | ($1.47M) | $3.22M | ($16.42M) |
| Net Income | ($239.56M) | ($239.56M) | ($308.48M) | ($126.80M) | $329.60M | ($125.02M) |
| EPS - Basic | ($3.46) | ($4.92) | ($6.47) | ($2.71) | ($2.81) | - |
| EPS - Diluted | ($3.46) | ($4.92) | ($6.47) | ($2.71) | ($2.81) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $80.24M | $158.93M | $241.36M | $228.01M | $556.26M | $244.93M |
| Accounts Receivable | - | - | - | - | - | $6.62M |
| Inventory | - | - | $12.02M | $6.92M | - | - |
| Accounts Payable | $5.17M | $7.23M | $6.59M | $10.98M | $2.50M | $3.77M |
| Current Assets | $655.99M | $390.29M | $651.85M | $476.77M | $628.24M | $258.91M |
| Total Assets | $824.91M | $556.54M | $831.69M | $704.96M | $809.18M | $340.39M |
| Current Liabilities | $62.92M | $40.05M | $73.67M | $75.92M | $36.76M | $27.33M |
| Long-term Debt | $49.70M | $51.32M | $101.75M | $102.79M | $100.96M | $35.62M |
| Total Liabilities | $626.01M | $563.29M | $624.02M | $228.96M | $213.40M | $96.49M |
| Stockholders' Equity | $198.90M | ($6.75M) | $207.67M | $476.01M | $595.78M | $243.91M |
| Retained Earnings | ($1.33B) | ($1.13B) | ($890.41M) | ($581.93M) | ($455.14M) | ($784.73M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($177.96M) | ($182.73M) | ($145.93M) | ($145.06M) | $287.96M | ($134.83M) |
| Investing Cash Flow | ($321.62M) | $162.97M | ($205.69M) | ($182.73M) | ($67.39M) | ($9.48M) |
| Financing Cash Flow | $415.40M | ($59.49M) | $362.72M | $1.45M | $94.86M | $7.44M |
| CapEx | $439.0K | $3.37M | $7.15M | $17.69M | $17.44M | $7.27M |
| Free Cash Flow | ($178.40M) | ($186.10M) | ($153.08M) | ($162.75M) | $270.52M | ($142.10M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 0.74 | 0.78 | 0.50 | 1.28 | 0.82 | 1.14 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | 1.0% | - |
| Return on assets | -29.0% | -43.0% | -37.1% | -18.0% | 40.7% | -36.7% |
| Return on equity | -120.4% | 3547.9% | -148.5% | -26.6% | 55.3% | -51.3% |
| Return on invested capital | -58.9% | -326.6% | -72.2% | -19.5% | 44.2% | -35.4% |
| Liquidity | ||||||
| Current ratio | 10.43 | 9.74 | 8.85 | 6.28 | 17.09 | 9.47 |
| Quick ratio | 10.43 | 9.74 | 8.68 | 6.19 | 17.09 | 9.47 |
| Cash ratio | 1.28 | 3.97 | 3.28 | 3.00 | 15.13 | 8.96 |
| Leverage | ||||||
| Debt / Equity | 0.25 | -7.60 | 0.49 | 0.22 | 0.17 | 0.15 |
| Debt / Assets | 0.06 | 0.09 | 0.12 | 0.15 | 0.12 | 0.10 |
| Debt / EBITDA | - | - | - | - | 0.31 | - |
| Interest coverage | -3.0x | -2.9x | -6.8x | -12.2x | 41.6x | -32.8x |
| Equity multiplier | 4.15 | -82.43 | 4.00 | 1.48 | 1.36 | 1.40 |
| Liabilities / Assets | 0.76 | 1.01 | 0.75 | 0.32 | 0.26 | 0.28 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | 0.01 | 0.18 | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | 67519d | 2015d | - | - |
| Days payable outstanding | 1119d | 2082d | 36983d | 3197d | 37d | 475d |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 6.9x | - | 1.6x | 2.2x | 1.5x | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | 1.5x | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -0.6% | 34.8% | -97.6% | - | - | -3.5% |
| Net income growth (YoY) | 0.0% | 22.3% | -143.3% | - | - | -0.7% |
| EPS growth (YoY) | 29.7% | 24.0% | -138.7% | 3.6% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 4.1% | -21.6% | 5.9% | - | - | -36.2% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | -56.4% | -20.1% | 144.3% | -24.5% |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
4/9
Neutral
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing uniQure N.V. against the 5 most active filers in the same SIC group.